Diagnostic utility of serum anti-Müllerian hormone in different phenotypes of polycystic ovary syndrome: a case-control study from a tertiary care centre
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262103Keywords:
PCOS, Anti-Müllerian hormone, Rotterdam criteria, Phenotypes, BiomarkerAbstract
Background: This study aimed to evaluate the diagnostic utility of serum Anti-mullerian hormone (AMH) in polycystic ovary syndrome (PCOS), to establish a cut off value, and to compare AMH levels across different PCOS phenotypes.
Methods: A case-control study was conducted in the Department of Obstetrics and Gynaecology at a tertiary care teaching hospital from July 2022 to June 2023. A total of 100 women aged 16-40 years were enrolled, including 50 PCOS cases diagnosed using the Rotterdam criteria and 50 age-matched controls with regular menstrual cycles. Participants underwent clinical evaluation, anthropometric assessment, transabdominal ultrasonography and serum AMH estimation using an enzyme-linked fluorescent assay. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal AMH cut-off for PCOS diagnosis.
Results: Mean serum AMH levels were significantly higher in women with PCOS compared to controls (7.10±2.70 ng/ml vs. 2.32±1.59 ng/ml; p<0.001). ROC analysis identified an optimal AMH cut-off of 4 ng/ml, yielding 90% sensitivity and 78% specificity, with an area under the curve of 0.895. Women with AMH ≥4 ng/ml had significantly increased odds of PCOS (odds ratio 31.9; 95% confidence interval: 10.2-99.9). Among phenotypes, AMH levels were highest in phenotype A and lowest in phenotype C.
Conclusions: Serum AMH is significantly elevated in PCOS and varies across phenotypes. It demonstrates excellent diagnostic performance and may serve as a useful adjunctive biomarker, particularly in settings where ultrasonography is limited.
Metrics
References
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of PCOS: a systematic review and meta-analysis. Hum Reprod. 2016;31:2841-55. DOI: https://doi.org/10.1093/humrep/dew218
Yang R, Qin Z, Zhou Z. Changes in the prevalence of PCOS in China over the past decade. Lancet Reg Health West Pac. 2022;25:100494. DOI: https://doi.org/10.1016/j.lanwpc.2022.100494
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria. Fertil Steril. 2004;81:19-25. DOI: https://doi.org/10.1016/j.fertnstert.2003.10.004
Teede HJ, Tay CT, Laven JSE, Dokras A, Mol BW, Woodruff TK, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-69. DOI: https://doi.org/10.1210/clinem/dgad463
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Legro RS, Escobar-Morreale HF, et al. Criteria for defining PCOS as a predominantly hyperandrogenic syndrome. J Clin Endocrinol Metab. 2006;91(11):4237-45. DOI: https://doi.org/10.1210/jc.2006-0178
Naidu J, Nandipati S, Srilatha K, Rao PV, Reddy BM, Prasad DK. AMH as a diagnostic marker in PCOS among Indian women. J Obstet Gynaecol India. 2020;70:189-95.
Ganesan S, Subramanian S, Ramanathan K, Balasubramanian N, Kumar V, Iyer P. Diagnostic utility of serum AMH in PCOS. Int J Reprod Contracept Obstet Gynecol. 2021;10:1332-8.
Ozturk TN, Duman C, Gorkemli H, Atmaca R, Yildirim G, Caliskan E. Role of AMH in different PCOS phenotypes. Arch Gynecol Obstet. 2017;296:1201-6.
Iliodromiti S, Anderson RA, Nelson SM, McConnachie A, Messow CM, Fowler PA. Technical and clinical challenges in AMH measurement. Clin Endocrinol (Oxf). 2021;95:18-26.
Van der Ham K, Laven JSE, Tay CT, Mousa A, Teede H, Louwers YV. AMH as a diagnostic biomarker for PCOS: systematic review and meta-analysis. Fertil Steril. 2024;122:727-39. DOI: https://doi.org/10.1016/j.fertnstert.2024.05.163
International Evidence-Based Guideline for the Assessment and Management of PCOS. Monash University, ESHRE, ASRM. 2023. Available at: https://bridges.monash.edu/articles/online_resource/International_Evidencebased_Guideline_for_the_Assessment_and_Management_of_Polycystic_Ovary_Syndrome_2023/24003834/1. Accessed on 25 March 2026.
Ramezani Tehrani F, Rahmati M, Mahboobifard F, Firouzi F, Hashemi N, Azizi F, et al. Age-specific AMH cut-offs for PCOS diagnosis. Reprod Biol Endocrinol. 2021;19:76. DOI: https://doi.org/10.1186/s12958-021-00755-8
Santhiya R, Habeebullah S. Correlation of PCOS phenotypes with AMH levels. Sahel Med J. 2021;24:15-21. DOI: https://doi.org/10.4103/smj.smj_50_20
Gunasheela D, Murali R, Appaneravanda LC, Gerstl B, Kumar A, Sengeetha N, et al. Age-specific distribution of serum AMH in Indian women. J Hum Reprod Sci. 2021;14(4):372-9. DOI: https://doi.org/10.4103/jhrs.jhrs_65_21
Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, et al. AMH as diagnostic tool for PCOS. J Assist Reprod Genet. 2014;31:1311-6. DOI: https://doi.org/10.1007/s10815-014-0300-6
Vural F, Vural B, Kardaş E, Ertürk Coşkun AD, Yildirim I. Diagnostic performance of AMH in PCOS. Arch Gynecol Obstet. 2023;307:1083-90. DOI: https://doi.org/10.1007/s00404-022-06874-w
Zhang Y, Liu H, Chen X, Wang Y, Li Q, Zhao J, et al. Diagnostic value of AMH and metabolic correlation in PCOS. J Ovarian Res. 2024;17:78.
Downloads
Published
How to Cite
Issue
Section
